|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.710 NZD | +0.27% |
|
+0.82% | +9.76% |
| 06-24 | NZX Biggest Gainers | MT |
| 06-24 | AFT Pharmaceuticals Gets US FDA Nod for Phase 3 Trial of Injectable Iron Therapy | MT |
| Market Cap | 389M 221M 194M 178M 166M 315M 21.1B 319M 2.14B 831M 10.36B 831M 812M 35.91B | P/E 2027 * |
19.7x | P/E 2028 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise Value | 419M 238M 209M 192M 178M 339M 22.72B 343M 2.3B 895M 11.15B 894M 875M 38.66B | EV / Sales 2027 * |
1.38x | EV / Sales 2028 * | 1.2x |
| Free-Float |
22.37% | Yield 2027 * |
0.88% | Yield 2028 * | 1.12% |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | +0.27% | ||
| 1 week | +0.82% | ||
| Current month | +1.37% | ||
| 1 month | -5.12% | ||
| 3 months | +10.42% | ||
| 6 months | +9.76% | ||
| Current year | +9.76% |
| 1 week | 3.66 |  | 3.77 |
| 1 month | 3.65 | | 3.97 |
| Current year | 3.35 | | 3.98 |
| 1 year | 2.54 | | 3.98 |
| 3 years | 2.37 | | 3.98 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Theodore Witek
BRD | Director/Board Member | 69 | 23/12/2020 |
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.27% | +0.82% | +35.90% | +1.37% | 221M | |
| -1.14% | -2.43% | +55.27% | +159.07% | 1,082B | |
| -1.41% | +0.32% | +67.02% | +60.48% | 633B | |
| -2.42% | +0.18% | +35.78% | +85.62% | 461B | |
| -2.79% | +1.37% | +31.00% | +23.05% | 338B | |
| -2.46% | -1.52% | +36.42% | +32.77% | 299B | |
| -2.20% | -0.93% | +27.50% | +40.62% | 291B | |
| -1.77% | +0.99% | -28.85% | -41.41% | 222B | |
| -2.06% | +1.63% | +25.09% | +64.34% | 202B | |
| -1.26% | +2.60% | +15.95% | +70.00% | 163B | |
| Average | -1.67% | +4.15% | +30.11% | +49.59% | 369.26B | |
| Weighted average by Cap. | -1.67% | +5.43% | +40.47% | +79.79% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 173M 151M 139M 129M 246M 16.48B 249M 1.67B 649M 8.09B 649M 635M 28.05B | 345M 196M 172M 158M 147M 279M 18.73B 283M 1.9B 738M 9.19B 737M 721M 31.87B |
| Net income | 19.71M 11.21M 9.81M 9.04M 8.39M 15.93M 1.07B 16.15M 108M 42.11M 525M 42.08M 41.16M 1.82B | 24.84M 14.12M 12.37M 11.39M 10.57M 20.08M 1.35B 20.35M 136M 53.07M 661M 53.03M 51.87M 2.29B |
| Net Debt | 29.84M 16.97M 14.86M 13.69M 12.7M 24.12M 1.62B 24.45M 164M 63.76M 794M 63.71M 62.31M 2.75B | 24.59M 13.98M 12.24M 11.28M 10.47M 19.88M 1.33B 20.15M 135M 52.54M 655M 52.5M 51.35M 2.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/07/26 | NZ$3.710 | +0.27% | 10,511 |
| 03/07/26 | NZ$3.700 | +0.82% | 3,160 |
| 02/07/26 | NZ$3.670 | +0.27% | 17,558 |
| 01/07/26 | NZ$3.660 | 0.00% | 441 |
| 30/06/26 | NZ$3.660 | -1.08% | 8,406 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
